Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix

<div>Graph (a) demonstrates the time of administration of degarelix and fibrinogen, platelets, and INR trends over the course of hospitalization. (b) Graph demonstrates PT and PTT trends over the course of hospitalization.</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix 